vs

Side-by-side financial comparison of Harmony Biosciences Holdings, Inc. (HRMY) and IHS Holding Ltd (IHS). Click either name above to swap in a different company.

IHS Holding Ltd is the larger business by last-quarter revenue ($254.0M vs $243.8M, roughly 1.0× Harmony Biosciences Holdings, Inc.). On growth, Harmony Biosciences Holdings, Inc. posted the faster year-over-year revenue change (21.1% vs 0.1%). IHS Holding Ltd produced more free cash flow last quarter ($178.6M vs $126.0M). Over the past eight quarters, Harmony Biosciences Holdings, Inc.'s revenue compounded faster (25.6% CAGR vs -22.0%).

Harmony Biosciences Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological and central nervous system disorders. Its primary market is the United States, with its core product serving patients living with narcolepsy and other sleep-related CNS conditions across adult and pediatric segments.

IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world, with operations across Africa and Latin America. It is the fifth-largest independent multinational tower company in the world.

HRMY vs IHS — Head-to-Head

Bigger by revenue
IHS
IHS
1.0× larger
IHS
$254.0M
$243.8M
HRMY
Growing faster (revenue YoY)
HRMY
HRMY
+21.0% gap
HRMY
21.1%
0.1%
IHS
More free cash flow
IHS
IHS
$52.6M more FCF
IHS
$178.6M
$126.0M
HRMY
Faster 2-yr revenue CAGR
HRMY
HRMY
Annualised
HRMY
25.6%
-22.0%
IHS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HRMY
HRMY
IHS
IHS
Revenue
$243.8M
$254.0M
Net Profit
$22.5M
Gross Margin
71.9%
83.6%
Operating Margin
15.8%
Net Margin
9.2%
Revenue YoY
21.1%
0.1%
Net Profit YoY
-54.6%
EPS (diluted)
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HRMY
HRMY
IHS
IHS
Q4 25
$243.8M
$254.0M
Q3 25
$239.5M
$455.1M
Q2 25
$200.5M
$433.3M
Q1 25
$184.7M
$439.6M
Q4 24
$201.3M
$253.8M
Q3 24
$186.0M
$420.3M
Q2 24
$172.8M
$435.4M
Q1 24
$154.6M
$417.7M
Net Profit
HRMY
HRMY
IHS
IHS
Q4 25
$22.5M
Q3 25
$50.9M
$147.4M
Q2 25
$39.8M
$32.3M
Q1 25
$45.6M
$30.7M
Q4 24
$49.5M
Q3 24
$46.1M
$-205.7M
Q2 24
$11.6M
$-124.3M
Q1 24
$38.3M
$-1.6B
Gross Margin
HRMY
HRMY
IHS
IHS
Q4 25
71.9%
83.6%
Q3 25
75.1%
47.5%
Q2 25
81.0%
51.3%
Q1 25
82.7%
51.4%
Q4 24
73.0%
72.1%
Q3 24
77.0%
52.0%
Q2 24
81.4%
52.5%
Q1 24
82.2%
39.1%
Operating Margin
HRMY
HRMY
IHS
IHS
Q4 25
15.8%
Q3 25
27.3%
35.1%
Q2 25
24.0%
33.8%
Q1 25
30.4%
37.1%
Q4 24
27.7%
Q3 24
33.2%
29.9%
Q2 24
12.4%
34.0%
Q1 24
33.7%
-1.7%
Net Margin
HRMY
HRMY
IHS
IHS
Q4 25
9.2%
Q3 25
21.2%
32.4%
Q2 25
19.8%
7.5%
Q1 25
24.7%
7.0%
Q4 24
24.6%
Q3 24
24.8%
-48.9%
Q2 24
6.7%
-28.5%
Q1 24
24.8%
-372.8%
EPS (diluted)
HRMY
HRMY
IHS
IHS
Q4 25
$0.38
Q3 25
$0.87
$0.44
Q2 25
$0.68
$0.10
Q1 25
$0.78
$0.10
Q4 24
$0.85
Q3 24
$0.79
$-0.61
Q2 24
$0.20
$-0.36
Q1 24
$0.67
$-4.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HRMY
HRMY
IHS
IHS
Cash + ST InvestmentsLiquidity on hand
$775.3M
$825.7M
Total DebtLower is stronger
$163.7M
$3.1B
Stockholders' EquityBook value
$870.2M
$-89.8M
Total Assets
$1.3B
$4.5B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HRMY
HRMY
IHS
IHS
Q4 25
$775.3M
$825.7M
Q3 25
$672.6M
$647.6M
Q2 25
$565.3M
$531.8M
Q1 25
$507.0M
$629.0M
Q4 24
$467.2M
$578.0M
Q3 24
$410.5M
$397.5M
Q2 24
$346.9M
$445.7M
Q1 24
$372.4M
$333.2M
Total Debt
HRMY
HRMY
IHS
IHS
Q4 25
$163.7M
$3.1B
Q3 25
$168.5M
$3.3B
Q2 25
$172.1M
$3.2B
Q1 25
$175.7M
$3.4B
Q4 24
$179.3M
$3.3B
Q3 24
$182.8M
$3.5B
Q2 24
$186.4M
$3.6B
Q1 24
$190.0M
$3.5B
Stockholders' Equity
HRMY
HRMY
IHS
IHS
Q4 25
$870.2M
$-89.8M
Q3 25
$835.1M
$38.1M
Q2 25
$773.1M
$-98.4M
Q1 25
$720.5M
$-184.4M
Q4 24
$659.2M
$-314.4M
Q3 24
$596.8M
$-284.7M
Q2 24
$538.6M
$-308.3M
Q1 24
$515.4M
$-163.2M
Total Assets
HRMY
HRMY
IHS
IHS
Q4 25
$1.3B
$4.5B
Q3 25
$1.2B
$4.7B
Q2 25
$1.1B
$4.5B
Q1 25
$1.1B
$4.4B
Q4 24
$999.2M
$4.2B
Q3 24
$928.1M
$4.6B
Q2 24
$858.4M
$4.5B
Q1 24
$847.0M
$4.6B
Debt / Equity
HRMY
HRMY
IHS
IHS
Q4 25
0.19×
Q3 25
0.20×
85.85×
Q2 25
0.22×
Q1 25
0.24×
Q4 24
0.27×
Q3 24
0.31×
Q2 24
0.35×
Q1 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HRMY
HRMY
IHS
IHS
Operating Cash FlowLast quarter
$126.2M
$246.9M
Free Cash FlowOCF − Capex
$126.0M
$178.6M
FCF MarginFCF / Revenue
51.7%
70.3%
Capex IntensityCapex / Revenue
0.0%
26.9%
Cash ConversionOCF / Net Profit
5.61×
TTM Free Cash FlowTrailing 4 quarters
$347.9M
$718.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HRMY
HRMY
IHS
IHS
Q4 25
$126.2M
$246.9M
Q3 25
$108.7M
$251.3M
Q2 25
$79.3M
$237.7M
Q1 25
$34.0M
$200.3M
Q4 24
$75.6M
$344.4M
Q3 24
$70.5M
$174.5M
Q2 24
$42.6M
$134.7M
Q1 24
$31.1M
$75.8M
Free Cash Flow
HRMY
HRMY
IHS
IHS
Q4 25
$126.0M
$178.6M
Q3 25
$108.7M
$189.2M
Q2 25
$79.3M
$197.7M
Q1 25
$33.9M
$153.2M
Q4 24
$75.0M
$282.9M
Q3 24
$70.5M
$122.3M
Q2 24
$42.0M
$74.2M
Q1 24
$31.1M
$14.8M
FCF Margin
HRMY
HRMY
IHS
IHS
Q4 25
51.7%
70.3%
Q3 25
45.4%
41.6%
Q2 25
39.6%
45.6%
Q1 25
18.3%
34.8%
Q4 24
37.3%
111.5%
Q3 24
37.9%
29.1%
Q2 24
24.3%
17.0%
Q1 24
20.1%
3.5%
Capex Intensity
HRMY
HRMY
IHS
IHS
Q4 25
0.0%
26.9%
Q3 25
0.0%
13.6%
Q2 25
0.0%
9.2%
Q1 25
0.1%
10.7%
Q4 24
0.3%
24.2%
Q3 24
0.0%
12.4%
Q2 24
0.4%
13.9%
Q1 24
0.0%
14.6%
Cash Conversion
HRMY
HRMY
IHS
IHS
Q4 25
5.61×
Q3 25
2.14×
1.70×
Q2 25
1.99×
7.36×
Q1 25
0.75×
6.52×
Q4 24
1.53×
Q3 24
1.53×
Q2 24
3.68×
Q1 24
0.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons